Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...

These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and chemotherapy-induced neutropenia.

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth ...

Net profit rose to $2.82 billion from $2.64 billion. Higher revenue from its key growth drivers--Entresto, immunology drug Cosentyx, breast-cancer treatment Kisqali, cholesterol treatment Leqvio ...

The global aspirin drug market is poised for substantial growth over the next decade ... offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the ...

Evernorth's growth pattern has remained consistent ... Over the next five years, Cordani said approximately $100 billion in specialty drug spend in the U.S. will be subject to biosimilar and generic ...

The global pharmaceutical regulatory affairs market size is expected to reach USD 14.34 billion by 2030, registering a CAGR of 7.17% from 2025 to 2030 The key factors driving the market growth are ...

To sum up, we can all expect a massive push towards global biotechnology. More than one factor is fueling such growth. Major sectors are taking strong steps towards drug development that benefits ...

Fibroblast growth factors (FGFs) signal through FGF receptor ... Recombinant FGF7 is Food and Drug Administration approved for the treatment of chemoradiation-induced oral mucositis.